Full-Time
Team Nurse
Beth Israel Deaconess Medical Center
10,001+ employees
Teaching hospital delivering patient-centered medical care
Compensation Overview
$32.24 - $55.32/hr
United States
In Person
Bachelor's
 Medical, Clinical & Veterinary (1) |
|---|
Get referred to Beth Israel Deaconess Medical Center
See people who can refer or advise you
- Graduation from an accredited nursing program is required.
- A Massachusetts Registered Nurse license is required.
- Basic Life Support certification is required.
- One to three years of related work experience is required, although new graduate registered nurses will be considered.
- Current CPR certification is required.
- Strong interpersonal, patient communication, and patient education skills are required.
- Advanced skills with Microsoft applications, including Outlook, Word, Excel, PowerPoint, or Access, and other web-based applications are required.
- Ability to communicate clearly and effectively in written and spoken English with medical center staff, patients, families, and external customers is required.
- Ability to make decisions guided by general instructions and practices, including recommendations for moderately complex problems, is required.
- Ability to analyze and interpret varied problems using direct observation, knowledge, and established precedents is required.
- Ability to follow procedures, set priorities, organize work, and seek assistance in difficult or unpredictable situations is required.
- Ability to demonstrate working knowledge of standard concepts, practices, procedures, and policies in varied situations is required.
- Ability to work collaboratively in small teams is required.
- Ability to provide professional, respectful, service-oriented customer service using active listening and problem-solving skills is required.
- Ability to remain calm in stressful situations is required.
- Ability to provide patient care to young adults, middle-aged adults, and elderly patients is required.
- Ability to use required protective equipment and work around infectious and bloodborne pathogens is required.
- Ability to perform medium physical work, including standing, walking, bending, grasping, manipulation, pushing, pulling, keyboard use, and reaching, is required.
- Coordinate and facilitate quality clinical management of a broad outpatient population across the continuum of care.
- Collaborate with providers to identify preventive care, evidence-based chronic disease management, and care coordination needs.
- Provide general and specific healthcare education and help patients identify and monitor self-management goals.
- Collaborate with community-based providers and follow up on emergency department visits and inpatient discharges.
- Assist providers with examinations, treatments, and procedures as needed.
- Provide skilled telephonic triage, assessment, education, collaboration, and coordination of healthcare and community resources.
- Perform direct patient care, including Annual Wellness Visits and Chronic Care Management for patients.
- Manage international normalized ratio results and provide Coumadin teaching using a standardized protocol.
- Administer vaccines and medications by parenteral, oral, rectal, or nasal routes according to provider orders and medication administration policies.
- Provide patient education for administered medications as appropriate.
- Perform nursing activities such as wound care and point-of-care testing under provider direction.
- Document all aspects of patient care accurately and promptly in the Electronic Health Record.
- Schedule tests and specialty-care referrals at the provider’s direction.
- Monitor and ensure follow-up of abnormal test and imaging results under provider direction.
- Oversee inventory and ordering of clinical supplies and equipment.
- Ensure safe, accurate, and clinically appropriate collection, storage, and processing of biologic specimens.
- Provide oversight and delegation and act as a clinical resource to unlicensed staff, including Medical Assistants, Certified Nursing Assistants, and nursing students.
- Provide ongoing education and training to practice staff.
- Maintain clinical knowledge and skills through consultation, literature review, continuing education units, and formal and informal education.
- Maintain compliance with mandatory annual organizational training.
- Use Patient Health Information only for treatment, payment, and healthcare operations purposes.
- Apply patient safety practices to prevent or eliminate patient harm and promptly report adverse events and near misses to Risk Management.
- A Bachelor's degree is preferred.
Beth Israel Deaconess Medical Center (BIDMC) serves as a teaching hospital in Boston affiliated with Harvard Medical School, offering a wide range of medical services across inpatient, emergency, outpatient, and urgent care. Its care model centers on delivering high-quality medical treatment to patients, supported by patient access initiatives like OpenNotes, which lets patients view clinicians’ notes online to improve understanding and engagement in their care. The hospital also supports education and research through its affiliation with Harvard, attracting funding for studies and training programs. BIDMC differentiates itself through its patient-centered approach, active patient engagement tools, and a broad network of urgent care centers and outpatient services that extend access to healthcare. The goal is to provide comprehensive, accessible, evidence-based medical care while advancing medical education and research.
Company Size
10,001+
Company Stage
Grant
Total Funding
$5.4M
Headquarters
Boston, Massachusetts
Founded
1996
Get referred to Beth Israel Deaconess Medical Center
See people who can refer or advise you
Simplify's Take
What believers are saying
- BIDMC won a June 2026 NIH R01 for ADAMTS13 and thrombotic risk research.
- June 2026 collaboration with NeuroXT extends BIDMC’s Alzheimer’s biomarker program toward clinical translation.
- BIDMC keeps attracting collaborators like Precision Neuroscience, Strados Labs, and the American Heart Association.
What critics are saying
- Kevin Tabb announced a 2027 departure, forcing a national CEO search during BILH integration.
- The ERISA settlement alleges bad retirement investments, signaling governance exposure and future fiduciary claims.
- BILH laid off roughly 600 people in 2024; another downturn can trigger service cuts and recruiting losses.
What makes Beth Israel Deaconess Medical Center unique
- Harvard-affiliated BIDMC still anchors BILH’s research engine and Dana-Farber cancer integration in 2026.
- Google’s AMIE feasibility study used BIDMC ambulatory patients, proving elite AI-clinical trial access.
- BIDMC’s Spatial Technologies Unit became Singular Genomics’ G4X Center of Excellence in March 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Paid Vacation
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%Scott rotig, MD, PhD, joins Pathology as new BIDMC Vice Chair of Hematopathology. Scott J. Rodig, MD, PhD is an internationally recognized hematopathologist, physician-scientist, and academic leader has joined the BIDMC Department of Pathology as Vice Chair of Hematopathology, and new position for the department. A Professor of Pathology at Harvard Medical School and an attending pathologist at Brigham and Women's Hospital and Dana-Farber Cancer Institute, Dr. Rodig brings more than two decades of clinical, research, and leadership experience at the forefront of hematologic malignancies. He has authored over 350 peer-reviewed publications, ranks among the top 1% of most-cited researchers in clinical medicine, and has played a pivotal role in discoveries and diagnostic innovations that have shaped modern lymphoma care. In his new role, Dr. Rodig will lead and strengthen collaboration between Dana-Farber's Hematologic Malignancies programs and BIDMC Pathology, advancing integrated clinical care, translational research, and education.
BIDMC wins NIH grant to study ADAMTS13 deficiency beyond rare clotting disorder. June 25, 2026 Beth Israel Deaconess Medical Center (BIDMC) has received a USD 1.63 million NIH R01 grant from the National Heart, Lung, and Blood Institute to investigate ADAMTS13 deficiency across a spectrum of thrombotic disorders - research that carries direct clinical relevance following the FDA approval of recombinant ADAMTS13 (Takeda's Adzynma) for immune thrombotic thrombocytopenic purpura (iTTP). The award funds two parallel lines of inquiry. The first leverages the Harvard TMA Research Collaborative (HTRC), a large single-center iTTP registry assembled by BIDMC investigators, to build predictive models for relapse, refractoriness, and mortality in iTTP patients. The grant also supports the first genome-wide association and admixture mapping studies in iTTP, aimed at identifying germline variants that may explain the disproportionate disease burden observed in certain populations. The second line extends beyond iTTP: using genomic and proteomic data from approximately 800,000 individuals in the UK Biobank and NIH All of Us datasets, the team will examine whether moderate ADAMTS13 deficiency - activity between 10% and 70%, versus the severe deficiency that defines iTTP - contributes to common macrovascular events including stroke, myocardial infarction, peripheral artery disease, and venous thromboembolism. ADAMTS13 cleaves ultra-large von Willebrand factor multimers, preventing pathological platelet aggregation in the microvasculature. In iTTP, severe enzyme deficiency drives diffuse microvascular thrombosis and end-organ damage. The hypothesis that moderate deficiency may also elevate risk for common thrombotic events remains unproven at population scale - making the large multiomic analysis a central scientific contribution of this award. The work could expand the clinical relevance of ADAMTS13 beyond rare thrombotic disease. Recombinant ADAMTS13 is now approved, and if population-scale data indicate that moderate deficiency contributes to stroke or myocardial infarction, the therapeutic and screening implications could extend well beyond the rare iTTP indication. Principal investigator Pavan K. Bendapudi has published on statistical modeling in iTTP and population-scale hemostasis datasets, positioning the group to execute both the registry-based and biobank-scale components of this work. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/
FAMU professor named Fulbright U.S. Scholar, will research AI in psychology at Czech University. June 18, 2026 By Heather Johnson TALLAHASSEE, Fla. - Florida A&M University (FAMU) psychology professor Huijun Li, Ph.D., has been named a 2026-2027 Fulbright U.S. Scholar, one of the most competitive and prestigious academic exchange designations in the United States. The Fulbright U.S. Scholar Program is administered by the U.S. Department of State's Bureau of Educational and Cultural Affairs. The program sends American faculty, researchers and professionals abroad each year to lecture and conduct research at host institutions in more than 130 countries. Li received the award in April, and she will travel to the Czech Republic in January 2027 for a seven-month appointment at Palacky University (UP), where she will conduct research and teach on the integration of artificial intelligence (AI) into psychological education and research. "I was very excited, and it's unbelievable because I know it is very competitive," Li said. "I'm looking forward to the cultural exchange, and I will be happy to share what I will learn with my students and colleagues." The project will center on an AI-powered app that includes mindfulness exercises and activities designed to help users recognize and constructively manage stress. Li said the timing aligns with the Czech Republic's national strategic plan, which calls for using AI to improve quality of life through 2030. "I really caught that point that this country is prioritizing AI in improving people's lives," she said. Li is a professor for FAMU's College of Social Sciences, Arts and Humanities (CSSAH) Department of Psychology and assistant director of the University's Center for Ethnic Psychological Research and Application. Her research focuses on youth mental health disparities within underserved populations, including mobile health technology, beliefs about the causes of mental illness, stigma, and barriers to care Since joining FAMU, she has secured more than $7 million in federal and foundation research grants and has authored or co-authored more than 50 peer-reviewed publications, books, book chapters and translated works. Li said the breadth of her output reflects the strength of her collaborative networks. "It's not only me doing all of these things," she said. "There are different research teams who work together, and we have become very productive." Her scholarship includes editing the 2019 volume "Handbook of Attenuated Psychosis Syndromes Across Cultures: International Perspectives on Early Identification and Intervention," published by Springer. The book draws on research from clinical programs across multiple countries to advance early identification and intervention for youth at risk for psychotic disorders. Her most recent funding award, a $399,971 grant from the National Science Foundation (NSF), launched in September 2025 and supports Boldly RISE, a student retention and wellness initiative at FAMU. The three-year project examines how social connectedness and behavioral health shape academic outcomes for first-year college students and is designed to inform retention strategies at institutions nationwide. Before joining FAMU, Li served as director of multicultural research at Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School. Li earned a doctorate in school psychology from the University of Arizona in 2003. She also holds an undergraduate degree in English and a graduate degree in applied linguistics, both earned in China. She served on the editorial boards of the Asian Journal of Psychiatry and Psychology in the Schools. Li was named FAMU's Emerging Researcher of the Year in 2014 and Distinguished Researcher in the non-STEM category in 2024.
NeuroXT and BIDMC Expand Collaboration to Advance AI-Driven Precision Treatment in Alzheimer's Disease. May 26, 2026, 08:36 ET Building on successful research collaboration, the two organizations enter a new phase of their research to accelerate the progress towards clinical impact BOSTON, May 26, 2026 /PRNewswire/ - NeuroXT, a leading biotechnology company specializing in AI-driven neuroimaging biomarkers, today announced the successful completion of its initial collaborative research with Beth Israel Deaconess Medical Center (BIDMC), and the signing of a new agreement to further expand their research into the precision treatment of Alzheimer's disease. The initial collaboration, announced in August 2024, focused on validating NeuroXT's MRI-based AI technology for precise estimation of Alzheimer's PET biomarkers. Building on this foundation, the new agreement will extend the research on data from patients who have received Alzheimer's therapies at BIDMC for over one year, further advancing the clinical utility of NeuroXT's imaging biomarkers. Complementing these efforts, NeuroXT also participated in the symposium "New Biomarkers in Early Alzheimer's Disease: Opportunities for Innovation," hosted by BIDMC in October 2025, convening global experts to share ongoing research and discuss emerging biomarker approaches "Our continued collaboration with BIDMC marks an important step toward translating AI innovation into clinical impact," said Joon-Kyung Seong, CEO of NeuroXT. The collaboration continues under the leadership of Dr. Daniel Press, Chief of the Cognitive Neurology Unit at BIDMC, alongside Dr. Chun Lim, Medical Director of the Cognitive Neurology Unit at BIDMC, reinforcing the collaboration's combined clinical and scientific expertise. For more details on NeuroXT's AI-driven innovations and its partnership with BIDMC, visit www.neuroxt.co.kr or contact us directly. About NeuroXT NeuroXT is at the forefront of biotechnology, focusing on AI-driven solutions for Alzheimer's disease. Under the leadership of CEO Joon-Kyung Seong, NeuroXT is committed to advancing Alzheimer's treatment through their cutting-edge AI imaging biomarker technology designed to predict individual treatment responses, ensuring the best therapeutic window for each patient. SOURCE NeuroXT
New drugs are primary care game changers, but pricey. April 21, 2026 New drugs approved in 2025 are poised to significantly improve the management of motion sickness, acute pain, urinary tract infections (UTIs), and chronic spontaneous urticaria. Gerald W. Smetana, MD, a professor emeritus of medicine at Harvard Medical School and Beth Israel Deaconess Medical Center in Boston, talked about new treatments in a presentation at the American College of Physicians Internal Medicine (ACP-IM) Meeting 2026 in San Francisco. "This is the first time in my 15-year history of giving this new drugs talk that I've given all four drugs a thumbs-up, with the potential to change practice," Smetana said during his presentation. Making headway against motion sickness. Motion sickness is a common problem with limited solutions, Smetana said. In December 2025, the FDA approved tradipitant, a novel neurokinin-1 antagonist that is the first new medication approved to treat vomiting induced by motion in more than 40 years. It works by blocking discordant messages from sensory and vestibular centers that promote reflex nausea. The approval was based on data from two phase 3 trials conducted on boats, in which the drug significantly reduced vomiting in participants with a history of motion sickness compared to placebo. In one study of 365 adults, about 18% and 20% of those who took 170 mg and 85 mg, respectively, of the drug daily experienced vomiting compared to approximately 44% of those who took placebo. Whether those without a history of the condition would benefit from proactive treatment remains unclear, Smetana said. Tradipitant is expected to be available this spring. While the final price has not yet been disclosed, estimated costs of more than $500 per eight-tablet bottle may be prohibitive and place it as a second-line treatment requiring prior authorization, Smetana said. William Callahan, DO, a family medicine physician at Jefferson Health in Jenkintown, Pennsylvania, noted that the drug is not approved for the prevention of nausea. Research is needed to compare the drug to the current standard, scopolamine transdermal treatment, and to understand how tradipitant treats nausea alone, Callahan told Medscape Medical News. "The clear benefit of tradipitant is its safety profile, with no reported anticholinergic side effects," Callahan said. Non-Opioid tackles acute pain. Suzetrigine targets the peripheral sensory nerves and dorsal root ganglia, reducing incoming pain signals, Smetana said. The drug represents the first new class of non-opioid pain medication in decades. The approval of the drug for moderate-to-severe acute pain was supported by data from two phase 3 studies that involved adults undergoing bunionectomy or abdominoplasty. Patients randomly assigned to a 48-hour course of suzetrigine showed a significantly shorter time to a reduction in their pain score than patients assigned to receive placebo. However, efficacy and safety for subacute and chronic pain are unknown, and data for use beyond 14 days are lacking. Notably, the studies used hydrocodone bitartrate/acetaminophen for comparison, and suzetrigine performed similarly, Callahan said. "This is huge: a non-opiate providing opiate-level pain control," he said. Gepotidacin: greater infection coverage. Epidemiologic data show that approximately one third of women in the US experience at least one UTI that requires antibiotics, Smetana said. Not all patients respond to first-line therapies, which include nitrofurantoin monohydrate, trimethoprim-sulfa, and cefpodoxime, Smetana said. The new drug gepotidacin works by blocking the activity of two bacterial topoisomerases and was approved to treat uncomplicated UTI by the FDA in March 2025. In studies that supported approval, gepotidacin was noninferior to nitrofurantoin. Cure rates in cases of resistant Escherichia coli were also higher for patients treated with the new drug than for those treated with nitrofurantoin. Clinicians may consider using the new drug in cases of known or suspected resistant bugs, Smetana said during his presentation. The main barrier to expanding use of gepotidacin may be the high cost of nearly $2000 for a 5-day course, Callahan said. And manufacturer cost assistance is only available to those with commercial insurance. With those considerations, the drug will likely be reserved for patients with documented resistance patterns or allergies that require this medication, he said. Top dollar for clearer skin. Remibrutinib, a selective tyrosine kinase inhibitor given orally, offers an option to help clinicians manage refractory chronic spontaneous urticaria in primary care, Smetana said. The drug was approved in September 2025. The condition, characterized by recurring hives or wheals for at least 6 weeks, is distinct from the physical urticaria caused by heat or skin pressure, he said. In two studies, patients treated with remibrutinib showed significant improvement in urticaria activity from baseline to 24 weeks with twice-daily dosing at 25 mg, showing sustained improvements for up to 1 year. No new safety concerns appeared, but given a theoretic potential for effects on the risk for infection, more postmarketing safety data are needed beyond 52 weeks, Smetana said. The drug may be preferable to patients who would choose oral treatment over injectable biologics despite the higher estimated 30-day cost of $4521 for remibrutinib vs $1472 for omalizumab and $3992 for dupilumab, he said. Callahan said chronic spontaneous urticaria can be difficult to treat, with significant trial and error needed to identify the best option for a patient, he said. "Many primary care practices are not set up to administer injectable biologic treatments, which makes this medication important," he said. "Further studies will be needed to compare remibrutinib to the current standards of care, specifically biologics, which would likely determine where it falls along the pathway of treatment." Smetana and Callahan reported having no relevant financial conflicts.